Bristol Myers Squibb reports symptom stability with Cobenfy in antipsychotic switch study and positive Phase 3 SCOUT-HCM results for Camzyos in adolescent oHCM.
Written By: Vennela Reddy, BPharm and
Pharmacally medical News Desk
Reviewed By: Pharmacally Editorial Team
Bristol Myers Squibb has reported new clinical data across two therapeutic areas, highlighting progress in both neuropsychiatry and cardiovascular disease. Findings include successful outpatient transition to Cobenfy™ (xanomeline and trospium chloride) with maintained symptom stability, alongside positive Phase 3 results for Camzyos® (mavacamten) in adolescents with obstructive hypertrophic cardiomyopathy (oHCM).
Cobenfy Switch Study Shows Symptom Stability in Schizophrenia
In an open-label outpatient switch study, adults with schizophrenia were transitioned from oral atypical antipsychotics to Cobenfy™ (xanomeline and trospium chloride), demonstrating stable symptom control over an 8-week period. The study was designed to reflect real-world clinical practice, assessing whether patients could be safely switched without clinical deterioration.
At Week 8, Positive and Negative Syndrome Scale (PANSS) total scores remained stable compared with baseline, indicating that symptom control was maintained throughout the transition. These findings suggest that switching to Cobenfy can be achieved without meaningful worsening of psychiatric symptoms in a controlled outpatient setting.
Cobenfy offers a differentiated, non-dopaminergic approach by targeting muscarinic receptors, marking a shift from traditional dopamine-based antipsychotics. This novel mechanism may provide an alternative option for patients who do not achieve adequate outcomes or experience tolerability issues with existing therapies.
The safety profile observed during the switch was consistent with prior studies, with no new safety signals identified. Overall tolerability supported continued treatment during the transition period.
Harald Hampel, MD, PhD, senior vice president, BMS noted that Cobenfy represents the first fundamentally new mechanism for schizophrenia treatment in decades, and the study was intentionally designed to help clinicians understand how to transition patients safely while prioritizing stability, safety, and clinical benefit.
Phase 3 SCOUT-HCM Trial Demonstrates Benefit of Camzyos in Adolescents
Separately, Bristol Myers Squibb announced positive results from the Phase 3 SCOUT-HCM trial (NCT06253221) evaluating Camzyos® (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This study represents the first evaluation of a cardiac myosin inhibitor (CMI) in adolescents aged 12 to <18 years with symptomatic oHCM.
The trial met its primary endpoint, demonstrating clinically meaningful improvements in functional capacity and symptom burden. Patients treated with mavacamten showed improvements in exercise capacity and New York Heart Association (NYHA) functional class.
Treatment with mavacamten led to reductions in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28, supporting its targeted mechanism in alleviating dynamic outflow obstruction, a key driver of symptoms in oHCM.
Safety findings were consistent with the established profile of Camzyos observed in adult populations, with no new safety concerns identified in the adolescent cohort.
These results position mavacamten as a potential first-in-class cardiac myosin inhibitor for adolescents and reinforce its role in advancing the treatment paradigm for oHCM.
Cristian Massacesi, MD, executive vice president, Chief Medical Officer and Head of Development, Bristol Myers Squibb highlighted that the findings support the potential to bring a meaningful, practice-changing therapy to younger patients and further strengthen the company’s leadership in the evolving CMI space.
Expanding Innovation Across Therapeutic Areas
Together, these updates reflect Bristol Myers Squibb’s continued investment in advancing therapies across diverse disease areas. The Cobenfy data support innovation in schizophrenia treatment through novel mechanisms, while the SCOUT-HCM results position Camzyos for potential expansion into adolescent cardiology. Further regulatory discussions and potential label expansions are expected based on these findings.
Reference
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride), 28 March 2026, Bristol Myers Squibb – Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM), 29 March 2026, Bristol Myers Squibb – Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
About the Writer
Vennela Reddy, B.Pharm is a pharmacy graduate with a keen interest in clinical research, pharmacovigilance, and medical writing, with a growing focus on publishable and scientific content development. In her words, she is passionate about translating complex medical data into clear, evidence-based communication.